An observational study in Gastric Cancer, sponsored by Centro di Riferimento Oncologico - Aviano. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-02-02.
Sponsored by Centro di Riferimento Oncologico - Aviano · Observational
Investigator propose the implementation of circulating biomarker monitoring, focusing on molecules related to the progression of gastric atrophy and/or associated with gastric cancer.
Monitoring these biomarkers will provide gastroenterologists with timely information on individuals at risk and, if values worsen during follow-up, will alert physicians observing these patients to evaluate them.
This monitoring will be offered to individuals who contact the IBO (Immunopatologia e Biomarcatori Oncologici) Unit at CRO (Centro di Riferimento Oncologico) in Aviano requesting an assessment of gastric function through pepsinogen and G17 gastrin level testing. Monitoring these biomarkers will provide a dynamic analysis of patients' gastric status, allowing for timely intervention in case of deviations from normal values. This proactive approach is important for the preventive management of gastric diseases, particularly for the diagnosis and monitoring of gastric atrophy and gastric cancer.
The IBO unit of the CRO in Aviano, together with the pathological anatomy and clinical units of gastroenterology, medical oncology, and surgery, will play a role in coordinating and implementing this monitoring program, thus contributing to the promotion of gastric health and the prevention of associated diseases.
2,851 studies on the registry are indexed under Stomach Neoplasms; 864 are open to participants now.
This study's planned enrollment of 192 is below the median of 274 across 670 observational studies indexed under Stomach Neoplasms.
Browse Stomach Neoplasms studies →Centro di Riferimento Oncologico - Aviano is the lead sponsor of 47 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study will be divided into two patient cohorts:
Exclusion Criteria:
Evaluate the association between the levels of selected biomarkers and the diagnosis obtained after endoscopic examination and histological evaluation of the biopsies taken.
The mean value of biomarkers level in positive and negative biopsy will be evaluated
Time frame: 36 months
Evaluate the prognostic potential of baseline levels of the biomarkers analyzed
Mean difference of biomarkers between responders and non responders
Time frame: 36 months
Identify biomarkers with the best relation with more advanced pre-neoplastic conditions and with neoplasia.
Mean difference of biomarkers level in subgroups of patients with the condition under investigation
Time frame: 36 months
Compare the predictive accuracy of risk between the DSCb test and the DSCb test with the addition of the best-performing biomarker
Accuracy will be calculated as number of patients correctly classified over the total number of patients.
Time frame: 36 months
Monitor test values during follow-up in subjects classified as high risk to assess the possible progression of the pre-neoplastic lesion
Likelihood ratio of the two tests will be reported
Time frame: 36 months
Monitor test values during follow-up in subjects with neoplasia to assess the potential of the test in therapeutic response
Test will be compared by mean of ROC curve analysis
Time frame: 36 months
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centro di Riferimento Oncologico - Aviano